YOKOGAWA-ELECTRIC
Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed the Single Cellome™ System SS2000, a single-cell analysis solution that utilizes high-resolution images captured with a confocal microscope to automatically and accurately collect samples of specific cells and intracellular components. The SS2000 will be released in Japan, the US, and China in February 2022, with release in other markets such as Europe to follow at a later date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006183/en/
Development Background
As the smallest unit of all living organisms, cells can greatly differ from one another; hence, there is a growing focus on single-cell analysis involving the isolation and handling of individual cells, as opposed to studying a population. In recent years, with improved analytical technology, it has become possible to analyze not only single cells but also specific molecules within them. Understanding the characteristics and functions of cells and mechanisms for cell development is a very effective means for clarifying the causes of diseases, preventing them, and verifying the efficacy of new drugs. This is essential for drug discovery research and the development of precision medicine and regenerative medicine.
Conventional techniques for the analysis of intracellular components have typically involved the disruption and collection of heterogeneous cell populations, which does not allow for sampling at the individual cell level, so many components cannot be collected and essential information on cell location and morphology is lost. In addition, as this sampling is done manually, throughput is low, and it is quite difficult for even experienced researchers.
Utilizing Yokogawa’s core imaging technologies that enable the real-time analysis of minute phenomena in live cells, the Single Cellome System SS2000 incorporates new technologies that automatically and accurately control sampling operations in order to support the performance of cutting-edge life science research.
Features
Yokogawa confocal microscopy technology enables the rapid, minimally invasive imaging of living cells. Based on the high-sensitivity analysis of the high-resolution 3D images, the cells are automatically and precisely sampled using precise positioning technology.
1. Optimal selection of cells or regions within cells according to set criteria
The SS2000 analyzes images of a large number of cells within a target range and classifies them by using provided criteria such as cytoplasm area and nucleus size. It then identifies which cells are suitable for analysis and determines their sampling location. Utilizing criteria such as distance from the nucleus, image analysis can even identify optimal regions within individual cells.
2. Reliable sampling of target cells and components within individual cells
The SS2000 directly samples only target cells without detachment, retaining all positional and morphology information in the culture plate. Furthermore, the utilization of high-resolution 3D images and precise positioning technology enables the selective sampling of target organelles and cytoplasm.
3. Samples can be used for a broad range of analyses
The collected cells and intracellular components can be used for a broad range of analyses, including genetic analysis and mass spectrometry. The optimum and efficient collection of target samples improves analytical sensitivity. In addition, single living cells that have been sampled can be grown in secondary cell cultures.
Hiroshi Nakao, a Yokogawa Electric vice president and head of the Life Business Headquarters, comments, "The newly developed Single Cellome System SS2000 is a solution that will play a key role in future cell research. It provides the potential to understand not only the characteristics of single cells, but also the networks and communication between cells, allowing us to ascertain pathological mechanisms. In an era where more and more people are living to the age of 100, Yokogawa will accelerate the development and provision of solutions to protect lives, health, and safety."
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 10:00:00 CET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
Energy Transition Solutions Powered by Choice: Trilliant to Share Expertise and Knowledge with Utilities and Smart Cities at Enlit Europe 20256.11.2025 09:00:00 CET | Press release
Product demonstrations and presentations from subject matter experts will highlight key industry insights and the importance of smarter infrastructure to connect systems, empower choice, and unlock performance Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, will be an exhibitor, presenter, and Silver Sponsor at Enlit Europe 2025. With product demonstrations on the exhibition floor and compelling presentations from thought leaders, Trilliant will highlight the importance of energy transition solutions, all powered by choice — that are flexible, scalable and interoperable. Taking place November 18- 20, 2025 in Bilboa, Spain, at the Bilbao Exhibition Centre (BEC), Enlit Europe 2025 is an event designed to connect industries, inspire action, and help Europe evolve into a dependable, decarbonised, and digitalised energy system. “As utilities and smart cities across Europe advance their energy transition
Red Hat Introduces Confirmed Sovereign Support for European Union6.11.2025 09:00:00 CET | Press release
Dedicated, EU-citizen-driven support delivers localized operational control and resilience for digital sovereignty Red Hat, the world's leading provider of enterprise open source solutions, today announced Red Hat Confirmed Sovereign Support for the 27 member states of the European Union to address the critical strategic imperative for digital sovereignty in Europe. This new support offering is purpose-built to deliver dedicated EU-citizen-driven technical support from within the EU for Red Hat software subscriptions, providing a new level of verifiable local control over critical IT operations. More and more European business leaders are looking to digital sovereignty as a way to help drive economic differentiation in a global marketplace, as well as insulate operations from geopolitical dynamics and safeguard EU data, technology and operations. At the same time, these leaders want to further cloud infrastructure resiliency and AI innovation goals through strengthened supply chain tra
IFF Benicarló Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing6.11.2025 09:00:00 CET | Press release
Local site sets a new benchmark for the fragrance industry IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, announced the installation of a nature-based hydrogen production facility at its Scent R&D and fragrance ingredients manufacturing plant in Benicarló, Spain. The site has partnered with Iberdrola, one of the world’s largest producers of renewable energy, to become the first in the fragrance industry to rely on renewable electricity for hydrogenation reactions used in manufacturing key fragrance ingredients. Aligned with the company’s commitment to Do More Good for people and planet, the site’s system can make 100 tons of clean hydrogen annually using renewable energy. It includes a built-in compressor to store hydrogen on-site — reducing the Life Cycle Assessment (LCA) of its products and supporting customers worldwide in achieving their decarbonization goals. This press release features multimedia. View the full release here: https://www
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe6.11.2025 08:00:00 CET | Press release
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
